Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured as ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

A new formulation of the best-selling cancer drug, Keytruda, appears to deliver similar blood levels of the medicine when it ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...

At age 20, while studying sports management and marketing in college, Sean Kukoleck's life was disrupted by cancer. He suffered his first-ever seizure, leading to the discovery of a large mass on ...